A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac’s CoronaVac shot, a study has found.
If you are not happy with the results below please do another search
50 search results for:
TScan Therapeutics secured clearance from the U.S. Food and Drug Administration for the company’s investigational new drug application to assess TSC-100 in treating patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).
The head of the World Health Organization (WHO) warned on Jan. 24 that it was dangerous to assume the Omicron variant would herald the end of COVID-19’s acutest phase, exhorting nations to stay focused to beat the pandemic.
At least 1 in 5 Americans have been infected with COVID-19. In other news, the U.S. Food and Drug Administration approved Gilead Sciences’ supplemental New Drug Application for Veklury (remdesivir) for adults and adolescents with COVID-19 who are not hospitalized but are at high risk of progression to severe COVID-19, hospitalization or death.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
A fourth dose of COVID-19 vaccine given to people over 60 years in Israel made them three times more resistant to serious illness than thrice-vaccinated people in the same age group, Israel’s Health Ministry said on January 23.
Beijing Olympics organizers said on Jan. 23 they had confirmed 72 cases of COVID-19 among 2,586 Games-related personnel entering China from Jan. 4 to Jan. 22, with no cases among 171 athletes and team officials arriving in that period.
Pfizer Inc. Chief Executive Albert Bourla said on January 22 that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.
The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.
Three U.S. studies show that a third dose of an mRNA vaccine is key to fighting the Omicron coronavirus variant, providing 90% protection against hospitalization due to COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) said on January 21.